ABBV-951 FDA Approval Status
ABBV-951 (foscarbidopa/foslevodopa) is a solution of carbidopa and levodopa prodrugs for continuous subcutaneous delivery that is being investigated for the treatment of motor fluctuations in patients with advanced Parkinson's disease.
- ABBV-951 is designed to provide a first-of-its-kind, 24-hour, continuous subcutaneous delivery of carbidopa/levodopa (CD/LD). Compared to oral CD/LD, it offers the potential for improvement in motor fluctuations in patients with advanced Parkinson's disease.
Development timeline for ABBV-951
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.